Ariad Pharm

Restructured Cancer Drug Agreement announced

Harvey J. Berger

Ariad Pharm with Merck Co, announced restructuring of its Ridaforolimus collaboration for the development, manufacture and commercialization. It may be noted that Ariad will receive $50 million upfront fee and said that it will be eligible to receive upto $514 million in regulatory and sales milestones. Ariad also will receive royalties on global net of ridaforolimus while all sales will be booked by March.